Welcome to the latest issue of Pharmaceutical Technology Focus magazine

As the number of specialised gene therapies continues to grow in the biotech sector, one particular subtype— those using adeno-associated virus (AAV) vectors—is becoming increasingly popular. In this month’s cover story we investigate several high-profile gene therapies that use these AAV vectors that are expected to be in the news in 2024.

Additionally, on the occasion of World TB Day, observed on 24 March, we take the opportunity to look at the need for new alternatives to treat HIV-TB coinfections. While several options are explored, experts say the landscape is alarmingly sparse.

Also in this issue, a freewheeling interview with the head of the Digital Therapeutics Alliance, explores the state of digital therapeutics—their development and use in the broader healthcare context. Don’t miss additional features on the growing role of patient advocacy organisations and priority review vouchers. All this and the latest news and analysis on the pharmaceutical and biotech industry.

Manasi Vaidya, editor

Go to article: Home | What’s next for AAV gene therapies in 2024?Go to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: phasetwoGo to article: Avenga Company InsightGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: Zenatek Company InsightGo to article: Simtra BioPharma SolutionsGo to article: In DepthGo to article: What’s Next for AAV Gene Therapies in 2024?Go to article: Traceability technologies tighten supply chain fakeryGo to article: Switching sales: Investigating the financial impacts of FDA’s priority vouchersGo to article: Is HIV-TB coinfection treatment entering a new frontier?Go to article: Patient organisations need to tackle transparency Go to article: AD/PD 2024: Eli Lilly’s donanemab hit with FDA delay Go to article: Q&A: Increasing awareness around digital therapeutics key to realising full potentialGo to article: Sponsored SupplementsGo to article: Lactalis IngredientsGo to article: BEA TechnologiesGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue